Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $2,480,120.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 4,000 shares of Medpace stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $620.03, for a total value of $2,480,120.00. Following the transaction, the chief executive officer owned 540,544 shares in the company, valued at $335,153,496.32. This represents a 0.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Medpace Trading Down 1.2%

NASDAQ MEDP traded down $7.48 during trading on Thursday, reaching $611.57. 198,148 shares of the company’s stock were exchanged, compared to its average volume of 344,156. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The company’s fifty day simple moving average is $559.49 and its 200-day simple moving average is $493.31. The firm has a market capitalization of $17.07 billion, a PE ratio of 35.85, a P/E/G ratio of 2.74 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Trading of Medpace

Institutional investors have recently added to or reduced their stakes in the business. BOKF NA increased its position in shares of Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares during the period. Valeo Financial Advisors LLC lifted its holdings in Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after buying an additional 21 shares during the period. UMB Bank n.a. lifted its holdings in Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after buying an additional 24 shares during the period. Schulhoff & Co. Inc. boosted its position in Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after acquiring an additional 25 shares during the last quarter. Finally, Balefire LLC boosted its position in Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after acquiring an additional 26 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MEDP has been the topic of several research reports. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. TD Cowen upped their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Robert W. Baird upped their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Finally, BMO Capital Markets increased their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.